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Abstract
The skeleton is the framework and in charge of body configuration preservation. As a living tissue, bones are constantly 
being formed and absorbed. Osteoblasts and osteoclasts are the main bone cells and balance between their activities indi-
cates bone health. Several mechanisms influence the bone turnover and RANKL/RANK/OPG pathway is one of them. This 
system, whose components are part of the tumor necrosis factor (TNF) superfamily, exists in many organs and could play 
a role in bone modeling and remodeling. RANKL/RANK pathway controls osteoclasts activity and formation. In addition, 
they are identified as key factors on bone turnover in different pathological situations. At the same time, OPG (RANKL’s 
decoy receptor) plays role as a bone-protective factor by binding to RANKL and prevention of extra resorption. The lack 
of balance between RANKL and OPG could result in excessive bone resorption. Probiotics, the beneficial microorganisms 
for human health, entail bones in their advantages. Recent studies suggest that probiotics could reduce inflammatory factors 
(for example TNF-α and IL-1β) and increase bone OPG expression. In addition, probiotics have shown to maintain bones 
in various ways. Although current evidence is not enough for definitive approval of probiotics’ efficacy on RANKL/RANK/
OPG, its positive responses from conducted studies are significant. Understanding of the probiotics’ effects on RANKL/
RANK/OPG pathway will help focus future studies, and assist in developing efficient treatment strategies.
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Introduction
Bones are the framework of body, and their health is strongly 
related to other organs, directly and indirectly. Bones have 
several functions such as protection of soft tissues and 
hematopoietic marrow, mechanical support for muscles, 
storage and release of vital ions, such as calcium as well as 
of growth factors which are stored in the matrix. Bone in the 
adult skeleton mainly contains two types of cells—osteo-
clasts and osteoblasts—and they are renewed continuously 
in response to different stimuli by a process of remodeling. 
With the term bone disorders is included osteoporosis, 
Paget’s disease of the bone, osteogenesis imperfecta, rick-
ets, osteomalacia, renal osteodystrophy, and hyperparathy-
roidism. Based on the World Health Organization (WHO) 
nearly 22% of women and 7% of men (older than 50) in 
27 countries of Europe have osteoporosis [1]. About 1.5 
million people are affected by osteoporotic-related fracture 
each year [2]. There are significant compositional, meta-
bolic, and architectural alterations with aging potentially 
leading to osteoporosis. Osteoporosis, as the most prevalent 
bone disorder, is characterized by two main complications: a 
progressive bone weakening and an elevated risk of clinical 
fractures. Thus, we can consider bone diseases (especially 
osteoporosis) as an epidemic issue, which is one of the most 
important concerns of medical society.
There are many risk factors that could lead to bone dis-
eases, including internal (genetic and aging) and external 
and modifiable factors (such as drugs). The use of drugs 
with harmful effects on the bone is increasing at an impres-
sive rate. They include glucocorticoids, aromatase inhibitors 
(such as anastrozole and letrozole), medroxyprogesterone 
acetate, thiazolidinediones, proton pump inhibitors (PPIs) 
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and antiepileptics, heparin- and serotonin-selective reup-
take inhibitors [3]. Instead, the most frequently used drugs 
for bone disease treatment (and prevention in some case) 
which are approved by FDA, include bisphosphonates (such 
as alendronate or ibandronate), hormone therapy (estrogens), 
calcitonin, denosumab (RANKL/RANK inhibitor), parathy-
roid hormone (PTH), and analogues. The results of studies 
on these drugs, which have been mostly done on postmeno-
pausal women, could not indicate conclusive evidence of the 
safety of these cures [4]. Since chemical treatments, despite 
being effective, have some side effects such as gastrointesti-
nal discomfort and musculoskeletal pain and hypocalcemia 
[5], alternative therapies such as the use of probiotics have 
now attracted researchers and practitioners.
The gastrointestinal tract of mammals hosts a various 
number of microorganisms, which are known as intesti-
nal microbiota. Many probiotics were originally isolated 
from the gastrointestinal tract, and according to the Food 
and Agriculture Organization (FAO) and the World Health 
Organization (WHO), probiotics are considered as live 
strains of microorganisms that have positive effects and con-
fer health benefits upon the host when administrated used 
sufficiently [6]. There are also definitions limited by the site 
of action, transfer format, characteristic of mechanisms or 
host [7]. Probiotics family includes Lactobacillus, Bifidobac-
terium, Enterococcus, Saccharomyces, Streptococcus, Leu-
conostoc, Bacillus, Escherichia coli, and Pediococcus [8]. 
Probiotics reveal their favorable effects on the host by four 
major mechanisms. Among them, they produce short-chain 
fatty acids (SCFAs) which are made through fermentation of 
indigestible polysaccharides and they help host immune sys-
tem to develop. The induction of T cells is one of the signs of 
immune system strengthening [9, 10]. Probiotics may modu-
late inflammatory status by promoting cytokines reduction 
as well. In fact, the evidence on probiotic downregulating 
of pro-inflammatory cytokines such as IL-6 [11] and Tumor 
Necrosis Factor [12] is numerous. Probiotics also protect the 
host via augmenting of the epithelial wall, increasing intes-
tinal mucosa coherency and by competitive elimination of 
pathogenic bacteria [13]. Thus, prevention of inflammatory 
bowel disease, which is determined by cytokine-induced 
epithelial harm, may be mediated by probiotics use [14]. 
Several studies demonstrated that some peptides, secreted 
from certain probiotics, increase the expression of heat-
shock proteins and could lead to Mitogen-Activated Pro-
tein Kinase (MAPK) activation [13]. It has been strongly 
supported by a lot of evidence that probiotics could repress 
gut inflammation through decrease of Toll-like Receptors’ 
(TRL) expression, prevent the Tumor Necrosis Factor alpha 
(TNF-α) entrance into mononuclear cells in blood and sup-
pression of enterocyte’s NF-kB (Nuclear Factor kappa-light-
chain-enhancer of activated B cells) signaling pathway [15]. 
TNF is among the most significant physiological inducer of 
NF-kappa B that is one of the major transcription factors 
that regulate normal cellular function and development of 
inflammatory osteolysis [16].
Indeed, bone is one of the organs that is impacted by pro-
biotics due to its dependency on gut, including the minerals 
and vitamins absorption [17]. Recently the term “osteomi-
crobiology” has been introduced for research in microbiota 
and bone health [18]. Under this term occur all aspects of 
bone and immune system arrangement in both homeostatic 
and pathogenic situations, including multiple cell types, 
signaling pathways, cytokines, and chemokines. Probiot-
ics seem to act like estrogen in osteoimmune regulation, by 
strengthening the structure of the bone via the T cells activ-
ity and also increasing the expression of the growth factor-β 
and inhibition of the production inflammatory cytokines 
[19]. The discovery of the RANKL/RANK/OPG pathway 
has led to major improvements in our imaginations of how 
bone modeling and remodeling are regulated [20].
With the present paper, we reviewed most recent studies 
about this triangle between bone, probiotics, and RANKL/
RANK/OPG on bone health.
RANKL/RANK/OPG pathway
Bone mainly contains two types of cells: osteoclasts and 
osteoblasts [20]. Osteoblasts are involved in bone formation, 
by producing several bone matrix proteins, and regularize 
osteoclast maturation by soluble agents and homogeneous 
interaction, which leads to bone reabsorption [21]. Osteo-
blastic stromal cells have an important role on osteoclasts’ 
development due to secretion of TNF superfamily [20]. The 
discovery of RANK/RANK/OPG system, which is a mem-
ber of this superfamily, allowed us to better understand bone 
biology. In detail, receptor activator of NF ligand (RANKL), 
receptor activator of NF (RANK), and osteoproteogerin 
(OPG) make a trio system, which regulate bone modeling 
and remodeling [20]. Amgen researchers discovered OPG 
while working on TNFR-related molecules [22]. OPG is a 
380 amino acid peptide, a soluble protein from TNF recep-
tor family. Osteoproteogerin gene expresses in many tissues 
like lung, heart, kidney, and bone [23]. It is called OPG 
upon its role of protecting bone from absorption. OPGL 
(OPG ligand) and ODE (osteoclast differentiation factor) 
were discovered together with OPG. Both OPGL and ODE 
are ligands for OPG, from TNF family, which help OPG to 
prevent osteoclastogenesis [22].
RANKL protein with 616 amino acids is enough to 
mature osteoclasts in absence of M-CSF (the macrophage 
colony-stimulating factor). RANKL mRNA mainly 
expresses in bone and lymphoid tissue [23]. RANKL/
RANK pathway controls osteoclasts’ activity and forma-
tion. In addition, they are identified as key factors on bone 
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turnover in the different pathological situations. At the same 
time, OPG (RANKL`s decoy receptor) plays role as a bone 
protective factor by binding to RANKL and prevention of 
extra resorption [20]. The lack of balance between RANKL 
and OPG could result in excessive bone resorption [24]. 
Citokines (including TNF-, TNF-, IL-1), PTH, vitamin D, 
glucocorticoids, and estrogen are some of the factors affect-
ing this system [23]. RANKL/RANK/OPG pathway revealed 
as an agent in the pathogenesis of giant cell tumor of bone 
(GCTB) and targeting its components has offered as a prom-
ising therapy of GCTB [25].
RANKL/RANK/OPG system and bone health
Osteoporosis, rheumatoid arthritis, bone heredopathia, 
familial Paget’s disease and bone tumor, all are diseases 
with involvement of RANKL/RANK/OPG system [26]. TNF 
receptor family does not have innate protein kinase property 
so they all need some operators to match with intra cyto-
plasmic part of them; in this case, these operators which are 
binding to RANKs cause to release TRAFs (TNF receptor 
associated factors.). TRAF6 is known as the main TRAF that 
affects RANK signaling [26]. Most of RANKL are formed 
by osteoblasts and T cells and RANK is mainly expressed 
on osteoclasts and dendritic cells. RANKL/RANK signal-
ing leads to bone turnover, which is prevented by OPG [27]. 
Bone turnover means replacing old bone tissue with new 
constituent in adults [26] and in these past decades RANK/
RANKL/OPG system has been described as a main system 
in bone modeling and remodeling [26]. Complementary 
research has shown that the cytokine-binding domain of 
OPG binds RANKL with much higher affinity as compared 
with RANK and prevents RANKL-induced osteoclastogene-
sis [28]. Recent studies show that RANKL/RANK/OPG sys-
tem is involved also in bone oncology. Lowering RANKL/
RANK/OPG ratio could inhibit bone cancer progression. In 
addition, some cancer cells also produce RANK [29].
Osteoporosis could be the result of immune system and 
bone turnover interaction [27]. One of the feasible post-
menopausal consequences is osteoporosis that is in the 
consequence of ovarian function interruption as well as 
gene-dependent estrogen effect on bone. In fact, RANKL’s 
and TNF’s expressions are enhanced by estrogen defi-
ciency [30] and also, men who are insensitive to andro-
gen show downregulation in their bone mass that identify 
androgen’s necessity in maintaining bone density [31]. 
Considering the effects of RANKL/RANK in osteoclasts’ 
activation, inhibition of RANKL in anyways (such as using 
a specific antibody) may be a proper treatment for osteo-
porosis [32]. In addition, bone erosions associated with 
rheumatoid arthritis are the consequence of osteoclasts 
activity in synovitis sites, which expresses RANKL. It has 
been observed in MRI (magnetic resonance imaging) that 
inflammation in bone and osteitis is associated with the 
presence of RANKL [33]. Familial expansile osteolysis 
(FEO) and Paget’s disease are rare inherited bone diseases 
and determinate by the excess of bone remodeling in the 
long bones. These diseases are associated with muta-
tions in genes that encoded RANK and result in enhanced 
RANK activity [34].
Bone health is threatened by various types of cancer 
during primary levels or therapies. Carcinoma cells could 
secrete some molecules like PTHrP (parathyroid hormone-
related protein) that activate bone desorption through 
RANKL/RANK/OPG system [35]. Multiple myeloma 
is a plasma cell cancer that is determined by a bunch of 
malignant bone marrow plasma cells which release immu-
noglobulin free light chain (FLC) [36]. One of the multiple 
myeloma complications is bone destruction via creating 
an imbalance between RANKL and OPG [37]. Interest-
ingly, phytoestrogens like genistein could augment OPG 
genesis in osteoblasts and subsequently inhibit RANKL 
gene expression. Additionally, raloxifene may reduce the 
osteoblast RANKL/OPG ratio by enhancing OPG expres-
sion and suppressing RANKL production [38]. Another 
disease that impacts bone structure is periodontitis (PD), 
an inflammatory malady which is devastating RANKL/
OPG pathway through proinflammatory cytokines [39].
So many factors inf luence RANKL/RANK/OPG 
pathway. Immune system has significant effect on bone 
modeling and remodeling. For example, B-lymphocytes 
release OPG while activated T and B-lymphocytes could 
release RANKL. Inflammatory cytokines impress bone 
turnover indirectly, like TNF, which is promoting osteo-
clastogenesis by RANK and RANKL. On the other hand, 
some other cytokines like IL-1, IL-6, IL-7, and IL-17A 
regulate RANK/RANKL/OPG [40]. Female sex hormones 
(estradiol and progesterone) strongly affect on RANK and 
RANKL, in which way decreasing of female sex hormones 
leads to increased RANK/RANKL signaling and it could 
be a reason for postmenopausal osteoporosis in women 
[41]. Lactoferrin may have restraining effect on RANKL 
and as well as on OPG secretion. Therefore, lactoferrin 
could promote RANKL/RANK ratio reduction and take 
part in osteoporosis prevention [27]. In a recent study, PTH 
appears to inhibit OPG function and stimulate RANKL 
[42]. RANK/RANKL/OPG system is also involved in the 
intervertebral disc degeneration process [43]. Again treat-
ment with WP9QY (or W9, a peptide which is consid-
ered as an analogous to one of the cysteine-rich domains 
in TNF receptor type I) peptide which binds to RANKL 
inhibits osteoclastogenesis and may prevent bone loss in 
OPG-deficient mice [44]. In Mucopolysaccharidosis type 
I which is a rare genetic disease, RANKL/RANK/OPG 
upregulation results in osteoclastogenesis [45].
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Probiotics and bone health
Recent observations demonstrate a connection between gut 
microbiota and bone health [46]. Generally, gut microbiota 
influence bone tissue in three ways, including modulation 
of nutrient absorbency at gut epithelium, regulating the 
mucosal and immune system and transposition of micro-
bic contents through the gut endothelial wall. Changes in 
gut microbiota compounds could disarrange bone turnover 
directly and indirectly as observed in diabetes, rheuma-
toid arthritis, inflammatory bowel disease, and obesity 
[47]. It is estimated that over 500 microorganisms’ spe-
cies and about bacterial cells (including fungi, protozoa, 
and yeasts) live in the gastrointestinal tract [48]. Evidence 
has shown that fetus could be influenced by maternal 
microflora. Right after birth, gut bacteria starts to pro-
liferate and continues to adulthood [49]. Gut microflora 
appears to have positive effects on different diseases such 
as cardiovascular disease, inflammatory bowel disease and 
bone discomfort like osteoporosis [50]. Gut microbiota is 
affected by some factors like diet, age, immune system and 
use of antibiotics [49].
In the last years some bacteria are added to food to level 
up their benefits and so called “probiotic” [51]. Literal 
meaning of probiotic is “for life” and short-chain fatty 
acids are their main products [50]. Probiotics appear to 
benefit humans in several ways, including immune system 
augment, deliver dietary energy, vitamin production and 
rise in metabolism (Fig. 1) [47]. Gut microbiota could 
regulate gut serotonin secretion, which interacts with bone 
cells and leads to bone modeling and remodeling [51]. 
Probiotics could also be used to decline postmenopausal 
bone loss by increasing gut epithelial stability, as well 
as the expression of tight junction proteins, or by reduc-
ing antigen transfer and lowering activation of intestinal 
immune cells [52]. Probiotics which are added to food 
cannot be deleterious to people and drug-resistance micro-
biota should not be used as probiotics. Food and agricul-
ture organization (FAO) and WHO published guidelines 
that help consumers on proper use of probiotics [53]. Their 
effects on vitamin absorption and distribution in human’s 
body could retain bone mass. At the same time, probiot-
ics’ interaction with immune system may activate anti-
inflammatory responses (like NF-kB pathway) and lead to 
bone turnover regulation [47]. In a recent study, probiotic 
supplementation for 6 months indicated reducing bone 
turnover rate in postmenopausal women [54]. Another way 
for probiotic to affect bone mass is their role in increas-
ing mineral absorption including calcium, phosphorous 
and magnesium, parallel with increasing endocrine factors 
like serotonin and incretins to promote bone health [53]. 
In addition, probiotics’ role in the prevention of bone loss 
in Type 1 Diabetes (T1D) has been also suggested [55]. 
An investigation revealed a probiotics’ protective effect on 
bone via inhibition of bone loss in ovariectomized (ovx) 
mouses, which are induced by Lactobacillus reuteri [46]. 
TNFα, which meliorates osteoclastogenesis and IL-1β, a 
downregulator of TNFα’s effects on bone, mRNA expres-
sion are diminished by probiotic consumption in contrast 
Fig. 1  Schematic representa-
tion of the principal effects of 
probiotics
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to vehicle treatment in ovx mice study [56]. Strengthening 
intestinal flora with probiotic LGG (Lactobacillus rham-
nosus GG) prevents intestinal penetrance and prohibits sex 
steroid-bone reabsorption while non-probiotic LGG do not 
have this sparing action [57]. Another study investigated 
the effects of Lactobacillus casei 393 (in fermented milk) 
on bone in ovariectomies rats and it indicated enhance-
ment in bone density and bone weight. Furthermore, tar-
trate-resistant acid phosphatase activity as an osteoclast 
factor meaningfully decreased [58]. Another study to cor-
roborate the effect of probiotics on the bone in animals has 
showed that Bifidobacterium longum as a probiotic could 
reduce bone reabsorption, enhance bone formation and 
control the microstructure of the femur [59]. More studies 
are required but bone-sparing effects of probiotics in oste-
oarthritis are considered [60]. While Lactobacillus helve-
ticus has been introduced for increasing bone density by 
upregulation of calcium uptake, researches also indicated 
that it is capable to generate valyl-prolyl-proline (VPP) 
and the bioactive peptides isoleucyl-prolyl-proline (IPP). 
Both of these peptides are able to prevent angiotensin-
converting enzyme (ACE) function, a stimulator of osteo-
clast reabsorption from Angiotensin I (Ang I), suppressing 
the initiation of Angiotensin II (Ang II) [53]. As whole, 
so far, most information in this subject matter is regarding 
osteoporosis and rheumatoid arthritis. A far as other bone 
diseases are concerned, there is little finding and more 
studies are needed [60]. A study on germ-free mice indi-
cates, gut microbiota modulates bone mass and this study 
presents the evidence of the mechanism including change 
in bone immune condition and hereby influenced bone 
resorption [61]. In addition, long-term colonization of the 
gut microbiota exhibited an enhancement in bone growth, 
in both longitudinal and lateral [62]. Based on a primary 
study, soymilk that fermented by Lactobacillus may inhibit 
trabecular bone loss and interestingly it could be like bis-
phosphonate alendronate in advantages [63]. Probiotics 
are almost safe and compare to their easy consumption. 
They have notable adjustment; all of these reasons make 
them a specific choice in bone treatment. Probiotics are 
accessible in various types including yogurt, foods with 
milk base, powder, capsules, or in form of ice cream and 
beer [64]. The effectiveness of probiotics may depends 
on the type of consumed probiotics [65]. There are dif-
ferent possible ways for probiotics to affect bone mass. 
One of these ways is the probiotics’ possible role in the 
synthesis of vitamins that participate in the metabolism of 
calcium and are required for the bone structure; including 
vitamin D, C, K, and folate. In addition, microbiota could 
generate short-chain fatty acids that lead to downregu-
lation on PTH and an abundance in mineral absorption. 
They could increase the bioavailability of minerals like 
calcium in phytate-rich food by releasing phytase; and by 
producing bioactive peptides like isoleucyl-prolyl-proline 
(IPP) and valyl-prolyl-proline (VPP) which are increasing 
the solubility of minerals. Some probiotics can amelio-
rate periodontal oxidative stress by diminishing NF-kB 
gene expression. INOS, which is a significant agent for the 
inflammatory response in the skeleton, would decrease by 
probiotics’ consumption by suppressing its gene expres-
sion. On the other hand, some species of probiotics can 
reduce proinflammatory cytokine expression in the gut, 
so enhancing calcium absorption by lowering inflamma-
tion in the epithelial cells [50]. The probiotics’ benefits 
on bone are reinforced by high amount of dietary calcium. 
Some of the probiotics’ major mechanism that affects bone 
includes enhancement of mineral solvability by releasing 
short-chain fatty acids, defeating the suppressing effects of 
phytate by releasing phytase enzyme, decreasing intestinal 
inflammation associated with increasing BMD, breaking 
glycoside bonds in the gastrointestinal track by Lactobacil-
lus and Bifidobacteria [50].
Probiotic and RANKL/RANK/OPG in bone
The effects of probiotics on RANKL/RANK/OPG system in 
bone are still under discussion, and findings are not enough 
for decisive result. A recent animal study demonstrated that 
RANKL had noticeable reduction in OVX mice that have 
been administered Lactobacillus acidophilus [66]. In other 
study, positive effect of L. reuteri to reduced bone RANKL 
expression has shown in OVX [53]. An 8-weeks survey on 
female mice in mild inflammatory state demonstrated, L. 
reuteri treatment influences expression of RANKL/OPG 
and IL-10 [67]. Recent studies suggest that probiotics could 
reduce inflammatory factors (for example TNF-α and IL-1β) 
and increase bone OPG expression [68].
GAS (streptococcus pyogenes) is one of the reasons for 
bacterial arthritis that can result in a serious bone problem. 
However, at the same time SLO (streptolysin), the product 
of GAS is shown to suppress RANKL signaling and increase 
activated osteoclasts’ apoptosis. Therefore, it brings a new 
attitude about GAS effects on bone health [69]. Inflamma-
tory bowel disease (IBD) could affect RAKL/RANK/OPG 
system and lead to higher bone resorption. Probiotics’ treat-
ment for IBD may influence this pathway and thus inhibit 
bone loss [70]. Another animal study has shown that probi-
otic treatment could suppress osteoclastogenesis factors such 
as TNF-α and IL-1β and RANKL/OPG ratio. Reduction of 
RANKL/OPG ratio may be the outcome of increasing OPG 
expression which is induced by probiotics in cortical bone 
[56]. In a study done in 2018, it has been identified that 
employing skim milk fermented by Lactobacillus paracasei 
(especially NTU101FM) it has anti-periodontitis property. 
The NTU101FM appeared to barricade RANKL-induced 
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osteoclast differentiation via its ethanol extract. This has 
been conducted by suppressing TRAP (tartrate-resistant acid 
phosphatase) activity and decreasing TRAP + multinuclear 
osteoclasts [71]. In a recent research, the combination of 
Hwangryun-haedok-tang (a usual cure in traditional Asian 
medicine) with Lactobacillus acidophilus fermentation has 
been used to modulate bone loss. Alongside with other bone 
benefits, fHRT (Hwangryun-haedok-tang fermented product) 
clearly prevents RANKL-induced osteoclastogenesis [72]. 
Lipoteichoic acid (LTA) of Enterococcus faecalis that might 
be an important stimulant for the inflammatory response 
has a considerable role to obstruct osteoclastogenesis acti-
vated by RANKL [73]. An investigation demonstrated that 
treatment with Lactobacillus para or the Lactobacillus mix 
modifies immune response in bone by decreasing cytokine 
and enhancing OPG expression. These findings strongly sup-
port the beneficial effects of probiotics in postmenopausal 
osteoporosis treatment [56]. Indeed, in a study on periodon-
tal disease, the probiotic supplementation did not decrease 
the RANKL expression while OPG significantly increased 
[74]. A reduction in RANKL expression has been observed, 
instead, in a 4-weeks study of L. rhamnosus-induced ovx 
mice [75]. Additionally, RANKL reduction was noticed in 
these studies a well using GeriLact (the mixture of 7 probi-
otic species) for postmenopausal women in 6 months [54], 
24-weeks study on postmenopausal women with consump-
tion of Bacillus subtilis (C-3102) [76] and a 4-weeks investi-
gation on L. reuteri ATCC PTA 6475 influence on ovx mice 
[46] (Table 1; Fig. 2).
Conclusions
RANKL/RANK/OPG system has an undeniable role in bone 
cells’ modeling and remodeling. In addition, probiotics have 
shown to maintain bones in various ways. Although current 
evidence is not enough for definitive approval of probiotics 
efficacy on RANKL/RANK/OPG, but its positive responses 
from conducted studies are significant. In conclusion, con-
firming the probiotic effect on RANKL/RANK/OPG path-
way requires extensive studies, including animal and human 
studies.
Table 1  Summary table of studies done to evaluate the “effects of probiotics on bone RANKL/RANK/OPG system”
RANK receptor activator of NF-kB, RANKL receptor activator of NF-kB ligand, OPG osteoprotegerin, TRAP5 tartrate-resistant acid phos-
phatase, uNTx urinary type I collagen cross-linked N-telopeptide, CTX collagen type 1 cross-linked C-telopeptide, BALP bone-specific alkaline 
phosphatase
Probiotic strains Treatment time Species Significant outcome Refs.
Lactobacillus acidophilus 6 weeks Mice (OVX) ↓ RANKL gene expression [67]
Lactobacillus reuteri (ATCC 6475) 4 weeks Mice (OVX) ↑ Bone volume fraction
↑ Bone mineral value
↑ Bone mineral density
↓ RANKL gene expression
↓ TRAP5 expression
[54]
Lactobacillus reuteri 6475 8 weeks Mice (dorsal surgery) ↑ Bone volume fraction
↑ Mineral absorption
↓ RANKL gene expression
↑ OPG and IL-10 gene expression
[68]
Lactobacillus paracasei and Lactobacillus plan-
tarum
6 weeks Mice (OVX) ↑ Cortical bone mineral content
↑ OPG expression
[57]
Lactobacillus rhamnosus (HN001) 4 weeks Mice (OVX) ↑ Serum osteocalcin
↓ RANKL, TNF-α and IL-17 
gene expression
↑ Bone volume fraction
[76]




Bacillus subtilis (C-3102) 24 weeks POSTMENOPAUSAL women ↑ Hip BMD
Lower uNTx
[77]
Lactobacillus reuteri ATCC PTA 6475 4 weeks Mice (OVX) ↓ RANKL
↓ TRAP5 expression
[46]
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